ALT only a few days ago traded close to net cash. Current market cap is USD 348 million. NVO market cap is USD 431 billion. It is Europe's largest company. 1238 times larger market cap than ALT. The phase 2b data for ALT's potential competitor was released a few days ago and appear to be as as good as the data for Wegovy (semaglutide)? Of course you still need phase 3 and approval. NVO only has a few products. How much of NVO's market cap is attributable to its GLP-1? Big pharma must be hungry for a weight loss drug of their own. Is there something wrong in this analysis?
NVO is on the uptrend; up it goes to the moon and beyond ALT, a penny stock, is on the downtrend; down it goes to the deepest ocean and beyond. Some major event on 1 Dec 2023?
https://www.marketwatch.com/story/a...e-obesity-drug-partnership-potential-524ea4f4 I find it difficult to understand why the market cap is only USD 325 million in this red hot weight loss drug market?
Well, now ALT is up 100% measured after the annoucement of phase 2b data, so everyone could have joined in without the risk of the announcement.
ALT up 147% from entry point after the announcement of phase 2b data, so you did not have to run the risk of the data. I hope you bought a position.